Intas Pharmaceuticals

Accord Healthcare partners with ITN Business for World Cancer Day to explore how innovative approaches are helping shape the future of cancer care

Retrieved on: 
Sunday, February 4, 2024
Partnership, MHRA, Patient, Intas Pharmaceuticals, Accord, Diagnosis, NHS, Disease, NHS England, Cancer, Medical imaging

The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1].

Key Points: 
  • The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1].
  • The programme also highlights how Accord has played a leading role in partnership with NHS England and MHRA to repurpose older medicines to help new cohorts of patients.
  • "With so many of us affected by cancer, this has been a really important and poignant programme to be part of.
  • Only through collaboration between cancer experts, industry, academia and patient organizations, can we make real progress toward a world without cancer.

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

Retrieved on: 
Friday, January 5, 2024
Health, FDA, Other Health, Research, Science, Pharmaceutical, Biotechnology, Food, Ustekinumab, EMA, MAA, Intas Pharmaceuticals, Inflammation, USD, IQVIA, Ulcerative colitis, CSO, Patient, Safety, Psoriasis, Psoriatic arthritis, BLA, Pharmaceutical industry

The BLA leverages the analytical similarity assessment data between EU and US sourced Stelara® and DMB-3115.

Key Points: 
  • The BLA leverages the analytical similarity assessment data between EU and US sourced Stelara® and DMB-3115.
  • It recorded USD 17.77 billion in sales (IQVIA Accumulative Sales) in 2022 and is one of the world’s best-selling biologics.
  • The rights of Dong-A Socio Holdings for R&D and commercialization were transferred to Dong-A ST in July 2020 for efficient project management.
  • Intas Pharmaceuticals plans to commercialize DMB-3115 through Accord BioPharma (US), Accord Healthcare (EU, UK, and Canada), and other subsidiaries around the world.

Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA® Biosimilar DMB-3115

Retrieved on: 
Thursday, January 4, 2024
Biology, Partnership, Food, Pegfilgrastim, Johnson & Johnson, Trastuzumab, Crohn's disease, FDA, Filgrastim, Ulcerative colitis, PASI, Intas Pharmaceuticals, Ustekinumab, Patient, Safety, Psoriasis, Medicine, BLA, Pharmaceutical industry

DURHAM, N.C., Jan. 4, 2024 /PRNewswire/ -- Accord BioPharma, Inc. the U.S. specialty division of Intas Pharmaceuticals Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for DMB-3115. DMB-3115 is a proposed biosimilar to STELARA®, a blockbuster drug developed by Janssen Biotech, Inc. and approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. In the U.S., STELARA recorded $13.9 billion in sales (IQVIA Sales in 2022) and is one of the best-selling biologics.

Key Points: 
  • In the U.S., STELARA recorded $13.9 billion in sales (IQVIA Sales in 2022) and is one of the best-selling biologics.
  • The announcement of DMB-3115's BLA acceptance comes as Accord BioPharma awaits a string of additional regulatory milestones.
  • The company has submitted three separate Biologics License Applications to the FDA for biosimilar versions of trastuzumab, pegfilgrastim, and filgrastim.
  • Accord BioPharma is planning to introduce several additional biosimilars to the U.S. market during the next five years.

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

Retrieved on: 
Friday, October 27, 2023
JAMA, Name, FDA, Trastuzumab, SCLC, Policy, Stomach, Food, European Commission, Cancer, ESCC, Intas Pharmaceuticals, American Medical Association, Independence, Lung cancer, MSI-H, European Medicines Agency, MSI, EC, Regulation of tobacco by the U.S. Food and Drug Administration, Carcinoma, Research, Commonwealth, Journal, Senior, Civil service commission, Growth, Clinical trial, Partnership, EMA, ASEAN, Patient, Nature Medicine, Fosun Pharma, Pharmaceutical industry, Accord

In 2021, Henlius granted Intas the exclusive rights to develop and commercialize HLX02 in the United States (U.S.) and Canada.

Key Points: 
  • In 2021, Henlius granted Intas the exclusive rights to develop and commercialize HLX02 in the United States (U.S.) and Canada.
  • Ping Cao, Senior Vice President and Chief Business Development Officer of Henlius, said, "Henlius and Intas first entered into a collaboration in 2018.
  • Binish Chudgar, Vice-Chairman & Managing Director, Intas Pharmaceuticals Ltd., said, "We are excited to reinforce our long-standing partnership with Henlius.
  • This collaboration will further bolster Intas' global oncology portfolio, underlining our commitment to delivering innovative healthcare solutions worldwide.

Accord Healthcare launches Accord Animal Health

Retrieved on: 
Wednesday, October 11, 2023
Intas Pharmaceuticals, Pressure, COVID-19, Vet, United Kingdom, Heart, Growth, Norbrook Group, Pet, Animal Health, Accord, Veterinary medicine

LONDON, Oct. 11, 2023 /PRNewswire/ -- Accord Healthcare, one of the fastest-growing pharmaceutical companies in Europe, committed to providing high-quality medicines at the point of care, is launching an Animal Health division to 'make it better' for Vets.

Key Points: 
  • LONDON, Oct. 11, 2023 /PRNewswire/ -- Accord Healthcare, one of the fastest-growing pharmaceutical companies in Europe, committed to providing high-quality medicines at the point of care, is launching an Animal Health division to 'make it better' for Vets.
  • There are now 34 million pets in the United Kingdom (UK), over 10% of which were acquired during the COVID-19 Pandemic1 .
  • We are setting up a new veterinary pharmaceutical division at Accord that firmly puts vets at the heart of everything we do."
  • "We are very excited to bring our extensive experience in pharmaceutical development, manufacture and commercialisation to Animal Health," said Paul Tredwell, Executive Vice President of Accord EMENA "We are thrilled to launch our new division, where, we have extensive plans for growth and I look forward to working with Bob to grow his team and business, supporting Animal health and the Vets that are so critical to animal wellbeing."

$545+ Mn Finasteride Market - Global Opportunity Analysis and Industry Forecast, 2021-2022 & 2031: Affordable Access to Generic Finasteride Fuel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Other Health, Clinical Trials, Research, Pharmaceutical, Science, Male, Finasteride, Laboratory, Prevalence, Hair loss, Sun Pharma, Medicine, BPH, Organon & Co., Market, Incidence, National library, Application, Porter's five forces analysis, Distribution, Aurobindo Pharma, Growth, Merck, Merck & Co., Benchmarking, Intas Pharmaceuticals, Organon, Video game, Generic drug, Retail, Marketing

The "Finasteride Market By Application, By Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Finasteride Market By Application, By Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • In addition, a rise in prevalence of benign prostatic hyperplasia (BPH) is expected to fuel the market growth.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the finasteride market analysis from 2021 to 2031 to identify the prevailing finasteride market opportunities.
  • The report includes the analysis of the regional as well as global finasteride market trends, key players, market segments, application areas, and market growth strategies.

EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar

Retrieved on: 
Monday, July 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Psoriasis Area and Severity Index, Intas Pharmaceuticals, Psoriatic arthritis, Partnership, CET, Ustekinumab, CSO, IQVIA, Dong Jiahong, Meiji, Marketing, Ulcerative colitis, Psoriasis, EMA, European Medicines Agency, Patient, PASI, Marketing Authorisation Application, MAA, Donga, III, MMA, Pharmaceutical industry, EU, Accord

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).

Key Points: 
  • Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
  • Accord , a wholly owned subsidiary of Intas Pharmaceuticals Ltd, submitted the MAA to EMA on June 23rd, and the EMA accepted the MMA submission on July 14th in CET.
  • The MAA submission is based on the results of an extensive analytical similarity assessment of DMB-3115 with that US and EU-sourced STELARA using current ‘state-of-the-art’ methods.
  • The MAA submission also comprised the results from the phase III multi-regional clinical trials in patients with plaque psoriasis (NCT04785326).

Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating Officer

Retrieved on: 
Tuesday, June 6, 2023
BSE, University, Senior, General anaesthetic, Marketing, University of Florida, PCC, NSE, Teva Active Pharmaceutical Ingredients, Intas Pharmaceuticals, Growth, Apotex, Anesthetic, Fine chemical, Science

Over three decades of experience spanning sales, marketing, regulatory, and operations

Key Points: 
  • Over three decades of experience spanning sales, marketing, regulatory, and operations
    MUMBAI, India, June 6, 2023 /PRNewswire/ -- Piramal Pharma Limited's (NSE: PPLPHARMA) (BSE: 543635) Piramal Critical Care (PCC) business, a producer of Inhaled Anesthetics and a global player in hospital generics, today announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO).
  • A Bachelor of Science in Marketing from University of Florida, Mr. Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy.
  • Peter DeYoung, CEO, Global Pharma, Piramal Pharma Limited, said, "I welcome Jeff to Piramal Critical Care and wish him all the success in his new role.
  • Speaking on the occasion of joining PCC, Mr. Hampton said, "It is truly an honor to be joining such a fast-paced, growth-oriented global company like Piramal Critical Care.

Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating Officer

Retrieved on: 
Tuesday, June 6, 2023
BSE, University, Senior, General anaesthetic, Marketing, University of Florida, PCC, NSE, Teva Active Pharmaceutical Ingredients, Intas Pharmaceuticals, Growth, Apotex, Anesthetic, Fine chemical, Science

Over three decades of experience spanning sales, marketing, regulatory, and operations

Key Points: 
  • Over three decades of experience spanning sales, marketing, regulatory, and operations
    MUMBAI, India, June 6, 2023 /PRNewswire/ -- Piramal Pharma Limited's (NSE: PPLPHARMA) (BSE: 543635) Piramal Critical Care (PCC) business, a producer of Inhaled Anesthetics and a global player in hospital generics, today announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO).
  • A Bachelor of Science in Marketing from University of Florida, Mr. Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy.
  • Peter DeYoung, CEO, Global Pharma, Piramal Pharma Limited, said, "I welcome Jeff to Piramal Critical Care and wish him all the success in his new role.
  • Speaking on the occasion of joining PCC, Mr. Hampton said, "It is truly an honor to be joining such a fast-paced, growth-oriented global company like Piramal Critical Care.

Aseptic Fill Finish Global Market Report 2023: Growing Demand for Aseptic Fill Finish Services Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 11, 2023
Chemicals, Plastics, Manufacturing, Molecule, Vaccine, APL, Charles River Laboratories, Hetero Drugs, Partnership, Fresenius (company), Patheon, Powder, Lonrho, Overalls, Research, Antibody, Type, Organization, Zenith Contract Services, Protein, Risk, Peptide, Approved Drug Products with Therapeutic Equivalence Evaluations, WuXi Biologics, Health, Robotics, Intas Pharmaceuticals, Oligonucleotide, Safety, Syringe, Fine chemical, Marketing, Glass, Airline, Oil

The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.

Key Points: 
  • The report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers.
  • In fact, a number of companies are involved in offering biologics fill finish services and small molecule fill finish services.
  • Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.
  • Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market.